RDD Pharma to acquire Naia Rare Diseases — 3 insights

RDD Pharma entered into a letter of intent to acquire Naia Rare Diseases in a move to boost its gastrointestinal drug pipeline.

Advertisement

What you should know:

1. Naia is developing a short bowel syndrome treatment and has other GI drugs in the pipeline.

2. RDD Pharma expects to close the deal after its merger with Innovate Biopharmaceuticals closes, forming 9 Meters Biopharma.

3. Naia will receive a combination of cash and shares in 9 Meters Biopharma if both deals close.

More articles on surgery centers:
CMS to pay for total knees in ASCs, boost ASC payment rate 2.6% in 2020: 4 details
With $60B+ deals this year, what’s in store for private equity in the future?
Texas health system building ASC — 4 insights

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.